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http://dx.doi.org/10.1016/j.ccr.2013.03.030SUMMARYIn mouse and human neural progenitor and glioblastoma ‘‘stem-like’’ cells, we identified key targets of the
Polycomb-group protein BMI1 by combining ChIP-seq with in vivo RNAi screening. We discovered that
Bmi1 is important in the cellular response to the transforming growth factor-b/bone morphogenetic protein
(TGF-b/BMP) and endoplasmic reticulum (ER) stress pathways, in part converging on theAtf3 transcriptional
repressor. We show that Atf3 is a tumor-suppressor gene inactivated in human glioblastoma multiforme
together with Cbx7 and a few other candidates. Acting downstream of the ER stress and BMP pathways,
ATF3 binds to cell-type-specific accessible chromatin preloaded with AP1 and participates in the inhibition
of critical oncogenic networks. Our data support the feasibility of combining ChIP-seq and RNAi screens in
solid tumors and highlight multiple p16INK4a/p19ARF-independent functions for Bmi1 in development and
cancer.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary
malignant brain tumor with a dismal prognosis despite multi-
modal therapies (Park et al., 2010). The systematic investigation
of critical cancer genes in genetically matched mouse models
has been enhanced by the recent molecular classification of hu-
man GBM in molecular subtypes and by the launch of RNAi
screens in vivo (Bric et al., 2009; Meacham et al., 2009; Verhaak
et al., 2010). However, in vivo RNAi screening for solid tumors re-
quires the rational selection of limited targets to overcome prac-
tical limitations in transplantation assays and potential off-target
effects.
The polycomb (PcG) repressive complex 1 (PRC1) is required
for adult stem cell functions and its activity is hijacked by cancerSignificance
Malignant gliomas are incurable brain tumors in which major t
tumors, the PolycombproteinBmi1 plays an oncogenic role, so
in vivo RNAi screens in a mouse model for glioma, we identifie
tially restored by dedicated pharmacological strategies. Our re
cally dissected by rational designing of shRNA screening in
integrating a plethora of signaling cues into defined transcrip
modulators downstream of Bmi1 oncogenic activity in glioma
important p16INK4a/p19ARF-independent functions.
660 Cancer Cell 23, 660–676, May 13, 2013 ª2013 Elsevier Inc.cells to silence tumor suppressive mechanisms (Sparmann and
van Lohuizen, 2006).
Ablation of PRC1memberBmi1 strongly affects the number of
normal neural stem cells (NSCs) in adult mice and delays
gliomagenesis, highlighting a critical role for Bmi1 in normal
and aberrant self-renewal. Bmi1 activity in NSCs relies in part
on the repression of the Cdkn2a locus (encoding for p16INK4a
and p19ARF), whereas additional functions in adult brain and
glioma homeostasis remain largely unknown (Molofsky et al.,
2003; Bruggeman et al., 2007). Bmi1 depletion in primary mouse
and human glioma-initiating cells (GICs) resulted in less aggres-
sive tumors and cancer cell apoptosis, respectively, which are
accompanied by a substantial transcriptome reprogramming
underscoring the importance of functionally characterizing the
BMI1 target genes and their pathways implicated in NSCumor-suppressor genes are genetically inactivated. In these
far poorly understood. By combining ChIP-seq for BMI1 and
d tumor-suppressor genes whose expression can be poten-
sults illustrate that validated oncogenes can be mechanisti-
vivo. Broadly, Bmi1 appears to endorse self-renewal by
tional outputs. Furthermore, Atf3 and Cbx7 are important
s, extending the previous observation that Bmi1 mediates
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Abdouh et al., 2009; Facchino et al., 2010).
Transforming growth factor (TGF)-b and bone morphogenetic
protein (BMP) signaling are important in NSC and brain tumor
cell homeostasis (Watabe andMiyazono, 2009). TGF-b supports
glioma cell proliferation, migration, and survival and affects
immunosurveillance (Seoane, 2009; Anido et al., 2010). BMP
signaling promotes the differentiation of embryonic neural pro-
genitor cells and, likewise, deprives glioblastoma stem-like cells
(GSCs) of self-renewal capacity by inducing astrocytic commit-
ment, in turn reducing glioma growth and associated mortality
(Lim et al., 2000; Chirasani et al., 2010). TGF-b/BMPdownstream
target Id1 is highly expressed in neural and glioma stem cells,
where it contributes to self-renewal. Id1 expression is directly
repressed by the stress-responsive ATF3 transcription factor
activated in a negative feed-forward loop upon TGF-b stimula-
tion in epithelial cells but not in GSCs (Kang et al., 2003; Anido
et al., 2010), suggesting a glioma-specific inactivation of the
stress-response pathway. The PcG pathway affects GSCs
response to BMP2 signaling due to cancer-specific silencing of
its receptor (Lee et al., 2008), but the extent and the implications
of the interplay between PcG, TGF-b/BMP, and stress-response
pathways are not yet fully understood.
In this study, we combined ChIP-seq and in vivo RNAi screen-
ings to investigate the mechanisms underlying Bmi1 functions in
neural progenitor cells (NPCs), GICs, and GSCs.
RESULTS
BMI1 Target Genes Are Regulated during Neural Stem
Cell Lineage Commitment and Deregulated in Bmi1
Knockout Brain
To determine the comprehensive BMI1 transcriptional network in
neural progenitor and brain tumor cells, we applied an ad hoc
ChIP-seq strategy to early-passage NPCs, astrocytes, and
glioma-initiating cells (GICs; see Supplemental Experimental
Procedures and Table S1 available online). Senescence-
impaired subventricular zone (SVZ) NPCs are endowed with an
extended lifespan but similar developmental potential (Molofsky
et al., 2006) and are highly tumorigenic in vivo when transduced
with the glioma-specific EgfrvIII, except when combined with
Bmi1 deletion that impairs their malignancy (Bruggeman et al.,
2007). Importantly, EgfrvIII;Cdkn2a/ GICs closely mirror the
human ‘‘classical’’ GBM (Verhaak et al., 2010).
In NPCs, BMI1 binding preferentially occurred at DNA ele-
ments largely overlapping with protein-coding genes. Strikingly,
despite a cell-type-specific expression fingerprint, the vast
majority of the BMI1 network of protein-coding and noncoding
genes appears to be independent of developmental stage and
tumorigenic potential (Figures 1A and S1A–S1D; data not
shown).
ChIP-qPCR in Bmi1/ and wild-type NPCs confirmed the
high sensitivity and specificity of our procedure (Figures 1B
and 1C). Also, we found that Bmi1 is important to maintain
H3K27me3 levels at binding sites (Figure S1E).
BMI1 binding globally correlates with low gene expression
levels in NPCs, while several target genes are differentially
expressed and linked in molecular networks in NPCs progeny,
such as astrocytes, oligodendrocytes, and neurons. Astrocyte-specific targets showed significantly lower expression in glial
cells than in postnatal neurons or oligodendrocytes, underscor-
ing the specificity of this analysis (Figure 1D and S1F–S1I). To a
large extent, BMI1 represses neuronal lineage-specific genes in
line with the astrocytic origin of SVZ-NPCs (Kriegstein and
Alvarez-Buylla, 2009). Finally, several BMI1 target genes showed
a remarkable transcriptional deregulation in brain cancers,
including GBM and medulloblastoma (Figures S1L and S1M),
in agreement with Bmi1 function to be important in these tumors
(Leung et al., 2004; Bruggeman et al., 2007).
To understand the consequences of Bmi1 ablation on target
gene expression, we performed global RNA-seq profiling of
NPCs propagated under growth factor defined conditions
and infected with doxycycline (dox)-inducible RNAi (BMI1 and
GFP) constructs, as well as of adult brain tissue. Only 4.8%
(61/1,270) of the neural BMI1 target genes systematically require
Bmi1 for continuous repression, such as the well-known PcG
targets Hox genes (Figure 1E), whereas Bmi1 loss had a greater
effect on the adult brain, with 500 genes upregulated exclu-
sively in the Bmi1/ mouse brain (Figures 1F and 1G).
Importantly, several key developmental regulators are BMI1
targets (Figure S1F) and some of these were found significantly
upregulated in Bmi1/ brain tissues, including Tal1, Runx3,
Pitx2, and Foxf1, as well as long noncoding RNAs (e.g., Igf2as
and Foxl2os; Figure 1G). Because of their direct functions in
neural lineage commitment and of related pathways such as
Notch, TGF-b/BMP and Wnt, deregulation of such BMI1 targets
is predicted to have widespread effects in neural development
beyond just affecting cell cycle control (Kioussi et al., 2002).
This may explain the incomplete rescue of Bmi1 developmental
defects by the sole codeletion of Cdkn2a (e.g., reduced brain
size and cerebellar foliation; van der Lugt et al., 1994; Brugge-
man et al., 2005).
Collectively, our data show that BMI1 binds to protein-coding
and noncoding genes critical for neural lineage commitment and,
possibly, relevant for brain cancers.
Bmi1 Binds to Genes Involved in TGF-b and BMP
Signaling in Normal and Tumor Cells
To understand if BMI1 target genes are interconnected into
specific signaling cascades, we performed ingenuity pathway
analysis (IPA).
Reasoning that mouse-human conserved BMI1 target genes
would be more informative in this analysis, we performed addi-
tional Bmi1 ChIP-seq profiling of primary human fetal NPCs
(Sun et al., 2009) and GSCs (Pollard et al., 2009). GBM1 and
GBM5 GSC lines were previously characterized for develop-
mental potential and tumorigeneicity and we further classified
them as ‘‘mesenchymal’’ and ‘‘proneural’’ GBM, respectively,
using gene set enrichment analysis (GSEA) and qPCR (Fig-
ure S2A; data not shown). Hence, our BMI1 profiles cover the
three best-characterized GBM subtypes.
Next, we analyzed pathways enriched in target genes com-
mon to all our BMI1 profiles, unraveling a core network of PcG
target genes associated with TGF-b and BMP signaling path-
ways (Figures 2A and 2B). Moreover, these pathways featured
the highest significance in mouse-human NPCs BMI1 target
genes and among genes upregulated in Bmi1/ mouse brain
(Table S2; data not shown).Cancer Cell 23, 660–676, May 13, 2013 ª2013 Elsevier Inc. 661
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Figure 1. Genome-wide BMI1 Target Genes and Their Expression Changes in Normal and Bmi1-Depleted NPCs and Mouse Brains
(A) Horizontal lines represent individual genes and dark blue high reads count. Input DNA control depicts random distribution. Supplemental experimental
procedures include detailed description of cells and bioinformatics. TSS and TES are transcription start and end sites.
(B) ROC plot of ChIP-qPCR validation of BMI1 peaks in NPCs. Results were expressed as enrichment over Bmi1 deficient NPCs (error bar = mean ± SEM; n = 2).
(C) UCSC genome browser view of ChIP-seq profiles for the indicated cells.
(D) BMI1 target genes expression in murine brain cells (Cahoy et al., 2008). P, postnatal; OPCs, oligodendrocyte progenitor cells; Gray, gray matter; cultured
astroglia, astrocyte-enriched tissue-cultured cell.
(legend continued on next page)
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of intracellular events including phosphorylation of SMAD2
(TGF-b) or SMAD1-5-8 (BMPs) ultimately leading to nuclear
translocation of SMAD4 and target gene regulation. A prominent
role for BMP cytokines during neural development has been
substantially demonstrated (Kriegstein and Alvarez-Buylla,
2009). To determine whether Bmi1 is important to coordinate a
transcriptional response to BMP signaling, we performed RNA-
seq in NPCs after dox-induced depletion of Bmi1 and exposure
to BMP4. Strikingly, even after a short-term and low-dose treat-
ment, BMI1 target genes showed preferential upregulation in
Bmi1-depleted cells (Figure 2C). RT-qPCR confirmed BMI1/
BMP4 targets to be more strongly upregulated in Bmi1-depleted
progenitors (Figures S2B and S2C).
Because BMP4 signaling is known to induce the differentiation
of embryonic neural progenitor cells into astrocytes (Lim et al.,
2000), we extended our RNA-seq profiles to NPCs treated with
fetal bovine serum (routinely used to differentiate NPCs),
including low and high concentrations (1%–10%) at different
time points. Unsupervised clustering based on BMI1 target
gene expression demonstrated that NPCs differentially respond
to signaling cues when Bmi1 level is artificially reduced (Fig-
ure 2D), indicative of a broadly altered response to differentiation
stimuli.
To understand the significance of this altered response, we
next assayed the proliferative and differentiation response of
Bmi1;Cdkn2a/ NPCs to morphogens. While TGF-b1 and
TGF-b2 did not significantly alter Bmi1;Cdkn2a/ NPCs growth
on laminin-coated dishes or Nestin and GFAP expression,
BMP4-treated NPCs significantly arrested when compared to
Cdkn2a/ NPCs, and their self-renewal was more drastically
compromised (Figures 2E and 2F; data not shown). This altered
response was accompanied by lower induction of the TGF-b/
BMP target Id1 and by unscheduled expression of its inhibitor
Atf3 (Figures 2G, S2D, and S2E; Kang et al., 2003). Atf3 dere-
pression occurred also in Bmi1 knockdown BMP4-treated
NPCs, underscoring a critical role of Bmi1 dose in regulating
Atf3 levels (Figure S2E).
Next to the known role for Id1 in primitive NSCs self-renewal
(Nam and Benezra, 2009), we provide evidence in adult NPCs
that Bmi1 cooperates with critical extracellular stimuli such as
BMPs in regulating tissue homeostasis, by fine-tuning the
expression of direct effectors or inhibitors of this pathway, as
exemplified by Id1-Atf3.
Conserved BMI1 Target Genes in Glioma Include
Tumor-Suppressor Genes
We reasoned that use of in vivo RNAi to ablate BMI1 target gene
function would help select out cancer genes relevant for glioma.
First, we verified that Bmi1 expression is not restricted to
specific GBM subtypes. We found evidence forBmi1 expression(E) Heatmap representation of RNA-seq profile of Bmi1/whole brain, littermate
or GFP shRNAs under a dox-responsive promoter. Common deregulated BMI1
n = 2).
(F) Log2 fold changes in transcript level of BMI1 target genes de-regulated in the
(Student’s t test; n = 2).
(G) RNA-seq profile validation by RT-qPCR. Selected significant comparisons ar
Error bars = ± SD. See also Figure S1 and Table S1.in the vast majority of patients with GBM (>89%), regardless of
the molecular subtype classification, and its expression corre-
lateswith average patient survival. Finally, immunohistochemical
analysis of high-grade glioma tissue microarrays using NKX2.2
and TRADD as proneural and mesenchymal markers, respec-
tively, demonstrated BMI1 expression to be independent of
GBM subtype markers (Figures S3A–S3C; data not shown).
Next, we generated an shRNA library of conserved BMI1
target genes in glioma (hereafter referred to as CBTG library)
by using cross-species conservation (Figure 3A; Table S3). The
CBTG library included all of the 129 BMI1 targets for which
three to six shRNAs were available (Broad Institute TRC1
library), several PcG genes, and ten shRNAs against epidermal
growth factor receptor (EGFR) as controls. This resulted in
a pool of 789 hairpins, each represented 130-fold when
100,000 cells are injected per animal. In bulk, seven animals
ensure 1,0003 representation of this library.
Loss ofCdkn2a and gain of EgfrvIII are sufficient to initiate glio-
magenesis in mouse models (Holland et al., 1998; Bachoo et al.,
2002), and we have previously demonstrated the homogeneous
and potent grafting efficiency of such GICs and that loss of Bmi1
does not reduce the number of tumor-initiating cells (Bruggeman
et al., 2007). These features suggest that our model is well suited
to accommodate a complex library of shRNAs.
To test whether our CBTG library contains tumor-promoting
shRNAs, which are predicted to increase tumorigenic potential
of our GICs, we set out a competition assay in vivo (Figure 3B).
Because Bmi1 expression in GICs could restrict target gene
expression, we reasoned that its in vivo depletion would in-
crease our ability to identify critical target genes. To this end,
we used the dox-responsive shBMI1 (BMI1i) and shGFP
(GFPi), and verified their ability to ablate protein expression in
mouse tumors (Figure 3C). Both GFPi- and BMI1i-CBTG tu-
mors showed similar histopathologic features of high-grade gli-
omas and survival kinetics regardless of Bmi1 ablation (Figures
S3D and S3E).
CBTG-modified cells were injected into recipient animals with
a ratio of 1 to 10 or 1 to 100 with non-CBTG-modified GICs, and
tumor formation was monitored by noninvasive biolumines-
cence. After 7–9 weeks, all of the animals showed luciferase
emission, except for non-CBTG controls (Figures 3D and 3E).
Furthermore, when glioma ‘‘stem-like’’ cell lines were derived
from three random tumors generated using as little as 1/100th
CBTG-modified GICs, only these cells contributed to tumor-
propagating lines (CBTG-modified cells were retrospectively
identified by fluorescence-activated cell sorting [FACS] because
they contain a dox-inducible shRNA against GFP; Figure 3F).
Single sphere analyses revealed that multiple shRNAs integra-
tions are infrequent events in our setting (Figure S3F).
Together, our data suggest that CBTG-modified cells within a
mixed tumor are endowed with a higher ability to initiate andcontrols, and of doxycycline-treated NPC bearing a lentivirus expressing Bmi1
targets normalized by controls are shown, FC > 1.5, p < 0.02 (Student’s t test;
Bmi1/ murine brains. Note that significant upregulation occurs only in vivo
e shown (two-way ANOVA).
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Figure 2. Bmi1 Is Important to Coordinate an Appropriate Transcriptional Response to TGF-b/BMP Signaling
(A) Two-by-two correlation of each ChIP-seq profiles to each other. Rows and columns (peaks) are sorted based on Spearman’s rank-order. Red and blue
represent high and low correlations, respectively.
(B) Ingenuity pathway analysis of mouse-human conserved BMI1 targets in NPCs and GBM ‘‘stem-like’’ cells from (A).
(C) RNA-seq profile of BMI1 targets in Bmi1-depleted NPCs upon short-exposure to BMP4 (3 hr; 10 ng/ml; FC > 0.5; Student’s t test).
(legend continued on next page)
Cancer Cell
In Vivo Forward Genetic Screen in Gliomagenesis
664 Cancer Cell 23, 660–676, May 13, 2013 ª2013 Elsevier Inc.
Cancer Cell
In Vivo Forward Genetic Screen in Gliomagenesispropagate the disease, indicating the presence of tumor-pro-
moting shRNAs in the CBTG library.
A Forward In Vivo Genetic Screen for Epigenetically
Silenced Tumor-Suppressor Genes in Glioblastoma
To uncover the identity of tumor-promoting shRNAs within all
CBTG tumors, we used HT-sequencing of glioma-enriched
shRNAs.
Tumor-enriched shRNAs correspond to tumor suppressor
genes (TSGs), whereas hairpins targeting oncogenes are
depleted during tumor grafting (Bric et al., 2009; Meacham
et al., 2009). Our screening relies on the orthotopic transplanta-
tion of GICs transduced with dox-responsive shRNAs targeting
Bmi1 (or GFP as control) and with a pool of puromycin-select-
able shRNAs directed against BMI1 target genes (CBTG
library). Reads obtained by sequencing tumor-derived hairpins
are normalized by the hairpins retrieved in the control cells
(i.e., before injection). In parallel, CBTG-modified GICs are
propagated in vitro for over six passages (3 weeks) to trace
single hairpin segregation under optimal growth conditions
(Figure 4A).
Previous studies have shown that 26%–40% of the initial
library complexity could be maintained in myc-driven lympho-
magenesis (Meacham et al., 2009). In a pilot experiment
comprising seven tumors (i.e. 1,0003 the CBTG library), we
noted a median complexity of 31% (16%–88%) independent of
the initial library complexity, which was retained in vitro (Figures
4B and 4C). By subsequent rounds of sequencing, we excluded
that in vivo dropout is strongly dependent on suboptimal satura-
tion (data not shown). Because each hairpin within our library
theoretically had 130-fold representation per mouse, loss of
shRNAs during gliomagenesis may be explained by either
random tumor clone outgrowth, or by functional depletion of
tumor-essential (or neutral) shRNAs.
To discriminate between these two possibilities, we first
analyzed the distribution of control shRNAs targeting EGFR,
which is required for efficient gliomagenesis. Significant deple-
tion of shRNAs targeted EGFR in mouse tumors, but not
in vitro. We demonstrated strong in vivo functional selection
confirming the feasibility of the screen (Figures 4D and S4A).
As an exception, one shRNA targeting simultaneously endoge-
nous EGFR and EGFRIII was reduced in vitro as well. EGFR
immunostaining confirmed protein expression in mouse gliomas
(Figure S3F).
Next, we performed the entire procedure de novo, reasoning
that if shRNAs segregation in vivo entails a functional selection,
enrichments should be reproducible. Hypergeometric distribu-
tion is indicative of a significant overlap between the two exper-
iments, after selection of hairpins whose enrichment was found
in three to five or more animals per experiment (Figure 4E; Table
S3; data not shown). Combining both experiments, we reached(D) BMI1 targets expression for NPCs treated with BMP4 or FBS as indicated. H
controls (n = 2).
(E and F)Cdkn2a/ and Bmi1/;Cdkn2a/NPCswere cultured as adherent mo
comparisons are shown (1-way ANOVA). Note that Bmi1-depleted NPCs are mo
(G) RT-qPCR of two adherent NPCs lines treated with BMP4. Results were
Cdkn2a/; ND = non-detected.
Error bars = ± SD. See also Figure S2 and Table S2.a final number of 20 tumors, nine of which were generated in
the presence of continuous suppression of Bmi1 expression.
After normalization on input cells, heatmap correlation between
in vitro and in vivo shRNA-seq showed that loss of Bmi1 is—to
some extent—neutral to the final pattern of shRNAs enriched
in vivo, and more importantly, that gliomagenesis promotes a
specific set of tumor-enriched shRNAs, underscoring the signif-
icance of this in vivo screen (Figure 4F; Table S3).
To identify candidate tumor-suppressor genes epigenetically
silenced in human GBM, yet limiting the contribution of ‘‘passen-
ger shRNAs’’ (i.e., enriched by either off-target or non-cell auton-
omous effects), we used several qualitative indicators. First, we
selected genes when at least two independent shRNAs were
present and enriched in both experiments (n = 106, p < 7.8 3
1081). Next, we searched for evidence of more than one copy
of the corresponding human loci in GBM, and for DNA methyl-
ation (Figure 4F). In fact, DNA hypermethylation and PcG binding
have been previously shown to overlap in human tumors (Ohm
et al., 2007; Schlesinger et al., 2007; Widschwendter et al.,
2007). Alternatively, pathway analysis can help identify relevant
candidates (Figures S4B–S4E). Notably, the vast majority of gli-
oma-enriched shRNA-targeted genes are expressed in adult
brain tissue and implicated in neural development, indicating
that preventing differentiation likely is a general feature promot-
ing gliomagenesis.
While genes not methylated in GBM yet passing the other
filters could still have tumor-suppressive functions, we focused
on six candidate tumor-suppressor genes that are potentially
restorable in human glioma (Figures 4F and S4E). Alx3 was pre-
viously indicated as an hypermethylated tumor-suppressor gene
in neuroblastoma and Ptprd was validated as a TSG in GBM
(Wimmer et al., 2002; Veeriah et al., 2009). Importantly, DNA
methyltransferase inhibitor 5-azacytidine alleviates repression
for these genes and even more effectively in combination with
dox-induced Bmi1 inhibition (Figure 4G).
Conversely, when we interrogated shRNAs significantly
depleted in vivo, and with specific criteria as in Figure S4F, we
identified candidate oncogenes that could be relevant for the
classical GBM subtype, including validated oncogenes in GBM
such as Ccnd2, and Klf6 (Bu¨schges et al., 1999; Kimmelman
et al., 2004). Overall, our data support the feasibility of a forward
genetic screen in solid tumors.
Suppression of Atf3 and Cbx7 in Bmi1-Depleted
Glioma-Initiating Cells Accelerates Tumorigenesis
and Impairs Animal Survival
Next, we selected out Atf3 and Cbx7 as candidate TSGs in gli-
oma because they showed dichotomous and context-depen-
dent functions in diverse tumor models and were not implicated
in glioblastoma (Scott et al., 2007; Thompson et al., 2009; Forzati
et al., 2012).eatmap represent RNA-seq data as normalized over dox-treated GFPi NPCs
nolayer (E) or neurospheres (F) in the presence of EGF/FGF2 ± BMP4. Selected
re sensitive to BMP4 cytostatic and differentiation activity.
normalized on the ubiquitous gene. DKO = Cdkn2a/; TKO = Bmi1/;
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Cancer Cell
In Vivo Forward Genetic Screen in GliomagenesisTo confirm their putative role as TSGs in glioma, we introduced
two single hairpins targeting eitherAtf3 orCbx7 in GICs, followed
by intracranial transplantation. EgfrvIII;Cdkn2a/;BMI1i cells
bearing two independent shRNAs per gene showed enhanced
tumorigenic potential, dramatically lowering animal survival
to < 3 weeks after transplantation (Figure 5A). As expected,
GICs induced large hypercellular neoplastic lesions with defined
margins but local invasion. Mitoses were readily seen, and, more
rarely, these tumors also showed large-sized anaplastic and
multinucleated giant cells, all features of grade IV World Health
Organization classification. However, only Atf3- and Cbx7-
depleted tumors comprehensively showed all the features of
human GBM such as multifocal necrosis, fibrovascular stroma,
non-neural cells such as osteoclasts, and hemorrhages (Figures
5B–5E, S5A, and S5B). Notably, all these features were more
often associated with Atf3 loss, indicating an inverse correlation
with animal survival. ATF3 immunostaining was often seen in
control tumors, with increased nuclear localization surrounding
apoptotic cells and was markedly reduced in Atf3-depleted
tumors (Figure 5D). RT-qPCR and western blotting confirmed
Atf3 knockdown (Figure S5C).
These shRNAs efficiently knockdown their targets while not
affecting tumor-sphere formation, and in vitro puromycin selec-
tion prevented cells devoid of the desired shRNAs to affect the
in vivo growth (Figures S5D and S5E).
To further exclude that in vivo enrichments would result from
pre-existing in vitro defects, we cloned six shRNAs targeting
Atf3 (2 shRNAs), Cbx7, Prdm1, Lmx1a, and Hand1 in dox-induc-
ible RNAi vectors and found that knockdown did not affect multi-
potency or differentiation, as gauged by sphere formation ability
and SOX2/GFAP FACS staining (Figure S5F).
Thus, underscoring the value of combined ChIP-seq/RNAi
screen for BMI1 target genes implicated in glioma, we validated
Atf3 and Cbx7 as TSGs in the context of the in vivo tumor
microenvironment.
ATF3 Nuclear Localization Is Excluded from High-Grade
Astrocytomas
To investigate ATF3 in human brain tumors, we performed tissue
array analysis to compare ATF3 protein levels between 63 low-
and high-grade astrocytoma/glioma and eight normal brain
tissue samples.
We found that only 38% (24/63) of the tumors showed patches
of nuclear staining for ATF3, and 80% of these (19/24) were lowFigure 3. BMI1 Target Genes RNAi Promotes Growth Advantage In Viv
(A) A conserved BMI1 target gene (CBTG) library is assembled pooling multiple
GBM5) BMI1 target genes. Additional hairpins include ten control shRNAs targe
(B) In vivo competition assay to assess the tumorigenic potential of 103 or 104 c
co-injected with 105 GICs. Transduced constructs are indicated.
(C) Validation of Bmi1 ablation in vivo. NOD/SCID mice intracranially injected w
20 mg/ml Dox and 0.01% sucrose drinking water from day 2 postinjection. Repres
of Bmi1 KD glioma IHC. Normal brain BMI1 staining is shown as control. T, tumo
(D) 1,000 CBTG-modified cells can contribute to tumorigenesis. Noninvasive b
luciferase- and nonmodified cells (no luciferase), in excess of 10-fold or 100-fold
(E) A representative set of animals from (D) is shown (group 1).
(F) FACS analysis of two representative GSC lines established from tumors initia
treatment (see B) confirms that these cells derive fromCBTG-modified cells. Note
indistinguishable.
See also Figure S3.grade (Figures 6A and 6B). The remaining immunoreactive
samples, including normal brain tissues, showed a cytoplasmic
staining. This feature was also seen in high-grade mouse lesions
(Figure 5D; data not shown).
Being a transcription factor, our data suggest that ATF3 regu-
lation in glioma may involve at least two layers: gene expression
and subcellular localization. ATF3 more often localized to the
nucleus of low-grade astrocytomas, but was either absent or
excluded from the nucleus in all the GBM samples, compatible
with an impaired function in high-grade tumors. In fact, evalua-
tion of data contained in the REMBRANDT database (molecular
repository for brain cancers) showed that patients with ‘‘interme-
diate’’ levels of Atf3 had a moderate but statistically significant
extended lifespan than patients with ‘‘downregulated’’ expres-
sion (Figure 6C). This analysis was based on patients with poten-
tial nuclear localization of ATF3, that is, those with astrocytoma
but not GBM. Age at diagnosis did not alter survival of patients
with downregulation of Atf3, because median age for this group
is in fact lower (median = 40–44 versus 50–54 years).
Even though in human gliomas Atf3 expression is generally
low, we found a moderately significant inverse correlation with
Bmi1 expression (p = 0.026; Figure S6A and S6B). Likewise,
patients with medulloblastoma (MD) and Atf3high-Bmi1low gene
expression levels had better survival times (data not shown).
Costaining for BMI1 and ATF3 in the glioma tissue array, how-
ever, indicated that BMI1 does not prevent ATF3 expression at
single cell level (Figure S6C), perhaps suggesting that BMI1
regulation may affect ATF3 levels rather than on-off switching.
Nonetheless, in cells co-expressing BMI1 and ATF3, the latter
was most often cytoplasmic, and as such transcriptionally
inactive.
Of note, Cbx7 expression showed similar correlation with
survival time for patients with glioma (Figure S6D).
Based on the retrospective nature of these analyses, we
conclude that BMI1 target gene Atf3 holds prognostic signifi-
cance for human brain tumors.
BMP Signaling and ER Stress-Activated ATF3 Engages
Open Chromatin Preloaded with AP1 Transcription
Factor
The brain microenvironment impairs gliomagenesis because
endogenous NPCs can release BMP7 and endovanilloids, lead-
ing to differentiation and ER stress-dependent apoptosis, re-
spectively(Chirasani et al., 2010; Stock et al., 2012). Becauseo
shRNAs per gene, targeting mouse (GICs and GL261) and human (GBM1 and
ting EGFR receptor and other PcG genes.
ells CBTG library-luciferase bearing cells (103 and 13 library representation)
ith GICs carrying a dox-responsive shGFP (GFPi) or shBMI1 (BMI1i) received
entative BMI1 IHC of a GFPi or BMI1i tumors. Inset shows higher magnification
r; N, normal.
ioluminescence performed on animals bearing tumors composed of CBTG-
. Note the 100-fold diluted shRNA modified cells high luciferase signal (Flux).
ted with 100-fold excess of nonmodified cells. Loss of GFP signal upon dox
that all CBTG-modified and 1003 dilution-derivedGSCs lines FACSprofiles are
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Figure 4. A Forward Genetic Screen to Identify Epigenetically-Silenced Tumor Suppressors in GBM
(A) RNAi in vivo experiment outline.
(B) Scatter plot correlation of plasmid library shRNA reads and transduced/selected GICs before transplantation (T0) or propagated in vitro under stem cell
conditions (left). The right plot illustrates correlation for GFPi or BMI1i tumor; r, Pearson correlation coefficient.
(C) The number of unique hairpins present in the plasmid library, T0 cells, and tumors from a first experiment comprising four GFPi and three BMI1i CBTG tumors
(5–7 weeks of in vivo selections).
(legend continued on next page)
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In Vivo Forward Genetic Screen in Gliomagenesisthis response is active in all transplantation-based studies
(including our in vivo RNAi screen) and Atf3 has been functionally
implicated in this signaling cascade, we investigated whether
BMP7 and the synthetic vanilloid arvanil would affect GICs
growth in soft agar. Indeed, arvanil totally abrogated colony
formation and neither epidermal growth factor (EGF)/basic
fibroblast growth factor (bFGF) nor TGF-b1 could rescue this
inhibitory effect, neither did the sole Atf3 overexpression or
knockdown significantly affect GIC growth in a bulk tumor-
sphere assay, underscoring the importance of upstream
signaling in Atf3 functions (Figures S7A and S7B; data not
shown). TGF-b1 promoted GIC growth in a Bmi1-dependent
manner but varying Atf3 levels did not alter this response
(Figure S7B), although we found that Bmi1 is important in re-
straining Atf3 expression in response to TGF-b1 in human
GSCs, and more broadly, to all the TGF-b/BMP ligands (Figures
S7C and S7D). Importantly, Bmi1 depletion relieved Atf3 repres-
sion in GSCs exposed to NPCs-conditioned medium (Fig-
ure S7E). Therefore, BMP7 stimulation and ER stress induction
using arvanil provide the most biologically relevant signaling
context to investigate the tumor suppressive functions of Atf3.
As we applied these experimental conditions to Bmi1-
depleted human mesenchymal GSCs, ATF3 staining increased
in both the cytoplasm and nucleus of GBM1 cells (Figures 7A
and S7F), and ATF3 ChIP-seq uncovered its binding both at
intergenic sites and nearby 2,192 RefSeq genes (Figures 7B,
7C, S7G, and S7H), some of which are highly expressed in
human GBM, notably in the mesenchymal subtype along with
the TGF-b signaling genes (Figures S7I and S7J).
Strikingly, ATF3 binding did not occur exclusively at ATF/
CREB sites as expected, but rather at DNA elements enriched
in the AP-1 motif (Figure 7D). ChIP- and DNaseI-qPCR revealed
ATF30s preference for DNaseI-accessible c-JUN-primed sites,
and Re-ChIP excluded that ATF3 and c-JUN binding was
affected by heterogeneity within our cell culture experiments
(Figures 7E–7H). Of note, genome-wide colocalization between
ATF3 and AP-1(FOS and JUN) is not restricted to glioma
cells because we confirmed it in K562 leukemia cells (data not
shown). Also, ATF3 binding sites in GBM1 usually bear one or
more CAGAC sites (60%), indicating that BMP7-activated
SMADs may be important in target recognition (data not shown).
Thus, once derepressed and activated, Atf3 binds to several
genomic sites in a signaling- and chromatin structure-oriented
manner.
Atf3 Participates in the Inhibition of Cell-Type-Specific
Critical Oncogenic Pathways
To investigate the functional implication of Atf3 activation in
GBM1 cells, we performed pathway analysis. The regulatory(D) Box plot illustrating the dropout of ten hairpins targeting EGFR in four GFPi tum
GICs reads. One-way ANOVA, p < 0.0001.
(E) Venn diagram depicted the tumor-enriched hairpin overlap between two indep
enriched in more than three animals per experiment (Exp1 = 9, Exp2 = 11; p < 0
(F) Heatmap correlation of each shRNA-seq profiles to each other. Rows and colum
red represent high and low correlations, respectively. Tumor-promoting shRNA w
G) RT-qPCR analysis of the human glioma cell line T98G treated for 5 days with eit
Statistics used two-way ANOVA. Note the cooperation between inhibitors.
Error bars = ± SD. See also Figure S4 and Table S3.network governed by ATF3 was enriched for genes downstream
of ERK/MAPK signaling, TGF-b, and, strikingly, all the master re-
gulators of the ‘‘mesenchymal transcriptional network (MTN),’’
like Cebpb, Stat3, Fosl2, and Runx1 (Figures 7C, 8A, and S7G;
Table S4; Carro et al., 2010). While the TGF-b/MTN targets are
likely to be mesenchymal-GSCs specific, the ERK/MAPK
signaling may be more broadly linked to ATF3 activation. In
fact mouse GICs and GSCs shared only 38% and 41% ATF3
targets genes, respectively, with GSCs, while pathway analysis
returned similar categories involved in stress-response and
MAPK signaling (Figure S8A; data not shown).
To unbiasedly analyze the more critical genes downstream of
ATF3, we performed RNA-seq profiling and pathway analysis
of GBM1 cells treated with BMP7/arvanil or left untreated.
This analysis highlighted the repression of ATF3-ERK/MAPK
downstream genes, such as Pi3kr2 and Pi3kr3, and MAP kinase
phosphatases (Dusp-1, -4, -9), consistent with the ATF3 tran-
scriptional repressive activity (Figure 8B; Table S4). RT-qPCR
confirmed that these genes are significantly downregulated
when GBM1 were propagated for 5 days under BMP7/arvanil
as opposed to conditions endorsing tumor self-renewal and
TGF-b oncogenic activity (EGF/bFGF/TGF-b1; Figure 8C). Atf3
knockdown in BMP7/arvanil-treated GBM1 cells suggested a
prominent role for Atf3 in the direct regulation of targets involved
in the ERK/MAPK pathway (Figure 8D).
In 293T cells treated with an alternative ER stressor (i.e., thap-
sigargin), we found that neither Atf3 overexpression nor ER
stress induction are sufficient to affect target genes in an Atf3-
dependent manner and that the TGFb/BMP-dependent SMAD
component appears to be required (i.e., SMAD3 overexpression
or TGF-b1 stimulation (Figures S8B and S8C).
Finally, Atf3 knockdown in T98G glioma cells (more amenable
to multiple infection/selection rounds) highlighted its role in sup-
porting arvanil-induced stress response (assessed by stress
beacons phospho-p38, -JUN, and -ATF2), while impairment of
ERK/MAPK signaling strongly relies on the BMP7 signaling (Fig-
ures S8D and S8E). Intriguingly, arvanil induced a feed-forward
loop toward Bmi1 expression, in vitro and in vivo (Figures S8F–
S8H; data not shown), supporting our conclusion that Bmi1
lies at the heart of GSC self-renewal by orchestrating the
cellular response to opposing signaling: cooperating with TGF-
b-induced self-renewal and opposing the cytostatic function of
BMP and ER stress-response pathways, at least in part via
repression of Atf3 (Figure 8E).
DISCUSSION
Bmi1 functions are important for normal and tumor develop-
ment, as we previously demonstrated in neurogenesis andors, and four in vitro propagated GICs, as compared to plasmid library and T0
endent in vivo experiments. One hundred six of 759 CBTG library hairpins were
.0001, hypergeometric distribution).
ns (normalized reads) are sorted based on Spearman’s rank-order. Yellow and
ere selected using criteria as indicated.
her 10 mM5-azacytidine (5-AzaC) ± dox or vehicle alone. Il5ra is not expressed.
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Figure 5. Suppression of Atf3 and Cbx7 in Bmi1-Depleted Glioma-Initiating Cells Accelerates Tumorigenesis and Impairs Animal Survival
(A) GICs co-expressing dox-responsive shBMI1 and two hairpins targeting Atf3 or Cbx7 were intracranially injected into recipient mice. Animals were sacrificed
on development of neurological signs. Statistics used log-rank (Mantel-Cox) test.
(B) Representative images of tumor-bearing brains.
(C) Representative hematoxylin and eosin (H&E) staining. White, black, red, and pink arrows denote multifocal necrosis, invasive margins, tumor angiogenesis,
and fibrovascular stroma, respectively.
(D) IHC staining for tumors from (C).
(E) Representative photomicrographs. Note the hemorrhages (arrows) in Atf3- and Cbx7-depleted tumors.
See also Figure S5.
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See also Figure S6.
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In Vivo Forward Genetic Screen in Gliomagenesisgliomagenesis (Bruggeman et al., 2005, 2007). In multipotent
cells, Bmi1 promotes long-term survival through the repression
of the Cdkn2a locus and it also prevents unscheduled dif-
ferentiation or changes in cell adhesion properties (Pietersen
et al., 2008; Bruggeman et al., 2009). To identify critical down-
stream BMI1 targets and signaling pathways in an unbiased
manner, we combined comprehensive BMI1 target identi-
fication (ChIP-seq) on mouse and human NPCs, GICs, and
GCs with dedicated in vivo shRNAi screening. This studyuncovered an important role for Bmi1 in neural progenitor
and glioma cells via the transcriptional repression of genes
involved in the cellular response to TGF-b/BMP and ER
stress-response signaling pathways. Mechanistically, the
prominent role for BMP signaling in neural tissue homeostasis
and its functional connection with the BMI1 pathway now
support a model in which BMI1/PcG are critically involved
in the fine-tuning of cellular responses to the local tumor
microenvironment.Cancer Cell 23, 660–676, May 13, 2013 ª2013 Elsevier Inc. 671
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Figure 7. ATF3 Binding to DNaseI-Acces-
sible Chromatin Preloaded with AP1
(A) IF for ATF3 inBmi1-depletedGBM1 cells grown
under conditions mimicking the antitumorigenic
response of endogenous NPCs. Cells were in-
fected with a dox-responsive shBMI1i, treated for
48 hr with doxycycline, 24 hr with ER stressor
arvanil, and 3 hr with BMP7.
(B) Horizontal lines represent ATF3 target genes in
GBM1 cells propagated as in (A) and dark blue
high reads count. Input DNA is shown as control.
(C) Selection of ATF3 target genes from (B).
(D) ATF3 binds to AP1 motifs. De novo and TFBS
motif search are shown.
(E) ChIP-qPCR for the indicated genes and anti-
bodies, in dox/BMP7/arvanil-treated GBM1 and
untreated cells.
(F) Box plot of data in (E) denotes ATF3 binding
to AP1 sites upon induction (unpaired Student’s
t test).
(G) GBM1 cell nuclei were digested with DNaseI or
left untreated and the indicated genomic regions
amplified by PCR (amplification inversely corre-
lates with accessibility). Note the higher and stable
accessibility of ATF3 binding sites as compared to
DnaseI-resistant N2 locus (n = 2; two-way
ANOVA).
(H) Re-ChIP-qPCR for ATF3 / c-JUN (left),
c-JUN / ATF3 (middle) and IgG / IgG (right)
immunoprecipitation experiments. N2 provides
background enrichment for each Re-ChIP (n = 2;
two-way ANOVA).
Error bars = ± SD. See also Figure S7 and
Table S4.
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In Vivo Forward Genetic Screen in GliomagenesisThe role of the context—namely the cell-type-specific onco-
genetic lesions and the extracellular signaling—seems to be a
primary determinant for the function of the genes identified in
this screening. For instance, Cbx7 is capable of promoting or
suppressing malignant phenotype conversions, and here we
report it to restrain gliomagenesis (Scott et al., 2007; Forzati
et al., 2012). Likewise, Atf3 has been previously proposed to
oppose tumorigenesis in colon and prostate cancer models
(Huang et al., 2008; Taketani et al., 2011). However, while our
data excluded Atf3 to provide growth advantage under our
experimental conditions, it remains possible that oncogenic
Atf3 functions may be elicited due to alternative signaling
cascades, differences in cell of origin or cooperating oncogenic
lesions, such as WNT signaling or H-rasV12 as shown in other
studies (Wu et al., 2010; Yan et al., 2011).672 Cancer Cell 23, 660–676, May 13, 2013 ª2013 Elsevier Inc.Because Atf3 is activated by both
developmental and stress pathways, our
model proposes a dual action for Bmi1
in desensitizing the Atf3 promoter to
TGF-b/BMP pathways and to ER stress
signaling, possibly by dampening the
extent and the duration of Atf3 induction.
The biological relevance for the TGF-b/
BMP-Atf3-Bmi1 axis in glioma is high-
lighted by the recent discovery that
endogenous NPCs exert a tumor sup-pressive function through the release of ER stressors and
BMP7 (Chirasani et al., 2010; Stock et al., 2012). The link
between PcG and ER stress-regulated Atf3 may be well
conserved because Atf3 is overexpressed in Ring1b mutant
zebrafish treated with thapsigargin, a potent inducer of ER
stress-dependent apoptosis (unpublished data).
Mechanistically, Atf3 has been previously involved in Id1
repression in the context of cell cycle inhibition by TGF-b in non-
transformed cells (Kang et al., 2003). Atf3 derepression also
correlated with Id1 inhibition in glioma cells, but only under a
different signaling cascade (tumor necrosis factor-a, not
TGF-b; Anido et al., 2010). However, our data suggest that the
Atf3-dependent transcriptional suppression of Id1 may not play
a pivotal role restraining gliomagenesis, though Id1 is a direct
ATF3 target in GSCs. This may be due to the BMP signaling
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Figure 8. Significance of ATF3 Functional
Activation
(A) Functional annotation of ATF3 target genes.
(B) RNA-seq for dox/BMP7/arvanil-treated GBM1
cells. Functional annotation of up- and down-
regulated genes is shown in red and green,
respectively.
(C) RT-qPCR for genes identified in (B) in GBM1
cells propagated under conditions promoting
(EGF, bFGF, and TGF-b1) or suppressing self-
renewal (doxycycline, arvanil, BMP7). Selected
statistical comparisons are show (two-way
ANOVA, p < 0.0001). Note that BMP7 and arvanil
abrogate TGF-b1 induction of ERK/MAPK and
MTN ATF3 target genes in Bmi1-depleted cells.
(D) RT-qPCR for genes in (C) in GBM1 cells ±
shATF3. BMP7/Arvanil treatment occurred 3 hr
before lysis. Two-way ANOVA indicates that ERK/
MAPK genes are rescued by lower Atf3 induction.
(E) A model for Bmi1 integration of opposing
signaling in NSCs/GSCs. Suppression of Atf3
enables oncogenic TGF-b and abrogates BMP
cytostatic activity, and occurs through the
canonical PcG-mediated transcriptional repres-
sion at developmental responsive elements (DRE).
The ER stress pathway can still activate Atf3
transcription, likely through regulatory stress-
responsive elements or chromatin regulation, and
PcG would restrict the extent and the duration of
this pathway.
Error bars = ± SD. See also Figure S8.
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In Vivo Forward Genetic Screen in Gliomagenesispromoting alternative uses for Id1 or to ID1 function itself being
dependent on the context in gliomagenesis as previously shown
(Anido et al., 2010; Barrett et al., 2012). Intriguingly, one surpris-
ing aspect of this study is our observation that Atf3 activity
may be modulated, if not predetermined, by a combination of
upstream signaling and local cell-type-specific chromatin struc-
ture, notably via ‘‘pioneer’’ transcription factors such as AP1.
Indeed, the SMAD(s)-, AP1-, and open-chromatin-aided target
gene selection is reminiscent of glucocorticoid receptor binding
(Biddie et al., 2011) and suggest a reassessment of the over-Cancer Cell 23, 660–simplified model that ATF/CREB DNA
binding sites drive ATF3 target selection
(Thompson et al., 2009). Because AP1
binding and open chromatin are cell-
type-specifically distributed but generally
available to all cells, this mechanism pro-
vides a molecular basis to investigate
GBM-subtype-independent therapeutic
strategies aiming at ATF3 functional
activation.
Human high-grade gliomas display a
remarkable intertumor and intratumor
variability, which poses several chal-
lenges to effective treatment. Key driving
and mutually exclusive oncogenic muta-
tions such as PDGFR (proneural), EGFR
(classical), and NF1 (mesenchymal) may
in part be responsible for GBM
heterogeneity. However, we showed evi-dence for the Bmi1-Atf3 axis to widely operate in all subtypes,
notably in glioma stem cells. Multiagent therapies exploiting
Atf3 tumor suppressive function should aim at overcoming its
cytoplasmic sequestration because we showed that the ER
stressor arvanil is not sufficient in achieving full nuclear function
of ATF3 despite reducing tumor proliferation and extending
animal survival. To this end, it remains to be precisely estab-
lished whether nuclear ATF3 is driven by phospo-SMAD(s) or
by down-modulation of ERK1/2 phosphorylation (Kang et al.,
2003; Inoue et al., 2004). Because BMP agonists are not676, May 13, 2013 ª2013 Elsevier Inc. 673
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In Vivo Forward Genetic Screen in Gliomagenesiscurrently available for therapy, it is tempting to speculate that
ERK inhibitors may act as a surrogate to reinforce ATF3 activa-
tion. Importantly, our study suggests that BMI1 may simulta-
neously suppress several genes that could have tumor-suppres-
sive function in glioma. As an epigenetic repressor, BMI1 activity
is potentially reversible in vivo. Most likely, dual action cytotoxic/
differentiation therapies may effectively impair gliomagenesis,
given that most of the tumor-promoting shRNAs/BMI1 target
genes are expressed in differentiated neural cell types.
The ChIP-seq/in vivo RNAi screen approach reported here
could be used to systematically test otherwise elusive bio-
markers and therapeutic targets for cancers. The use of induc-
ible RNAi should be considered to avoid affecting tumor initiation
when testing nonsilent genes or to enable cooperative testing of
drugs and RNAi. Also, current next-generation RNAi technolo-
gies may further limit the contribution of passenger shRNAs or
hairpins with inefficient knockdown (Fellmann et al., 2011).
In summary, our study integrates a well-characterized mouse
model for glioma, genome-wide BMI1 binding profiles, and
an in vivo forward genetic screen with the ultimate goal of iden-
tifying clinically relevant cancer genes, with possible transla-
tional implications.
EXPERIMENTAL PROCEDURES
Primary cell derivation and propagation, ChIP and immunohistochemistry pro-
tocols were previously described (Bruggeman et al., 2007; Gargiulo et al.,
2009), Detailed protocols, plasmids, and antibodies are reported in the
Supplemental Experimental Procedures. Patient-derived line samples were
not generated for this study (referenced elsewhere). All animal experiments
were conducted in compliance with the European Union guidelines for the
use and care of laboratory animals and were reviewed and approved by the
animal ethics committee (DEC) of the Netherland Cancer Institute.
RNAi Screen
GICs cells were infected with a dox-inducible shRNA against GFP or BMI1,
FACSpurified byGFPexpression, and43106 cellswere infectedwith a shRNA
library targeting a 159 gene set (789 hairpins), pooled from individual clones
from the TRC library (Open Biosystems), and packaged in a high titer lentiviral
prep (>2 3 105 IFU/ml). Twenty-four hours after infection, GICs cells were
puromycin selected. Next, 1 3 105 GICs cells per mouse, representing >125-
fold enrichment over the library, were injected intracranially into NOD/SCID
mice. For the number of actual integrations, 4.5 3 105 noninjected remaining
cells were used as a calibrator. Disease progression was monitored by symp-
toms 5–7 weeks after injection, and tumor tissues were surgically resected.
Hematoxylin and eosin staining on one representative tumor confirmed high-
grade glioma formation. shRNAs were amplified from genomic DNA using
primers that include adaptors for Illumina Hiseq sequencing. After PCR ampli-
fication of hairpins, sequencing was used to identify constituent shRNAs in
each sample. The sequence reads were aligned to a list of all shRNAs of the
TRC library. Fold change in hairpin representation after proliferation in vitro or
in vivo was determined by comparing shRNA representation in each sample
to that in a control cell population remaining after cell intracranial injection.
ACCESSION NUMBER
The GEO accession number for the raw data for ChIP/RNA-seq data reported
in this paper is GSE33912.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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